Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026)
Neumora Therapeutics' quarterly Other Accumulated Expenses came in at $736000.0 in Q1 2026, up 79.95% year-on-year from $409000.0 in Q1 2025, and up 1.66% quarter-over-quarter from $724000.0 in Q4 2025.
Neumora Therapeutics has reported Other Accumulated Expenses for 5 years, with the latest figure at $736000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 79.95% year-over-year to $736000.0; the trailing twelve-month figure through Mar 2026 stood at $736000.0 (up 79.95% YoY), and the FY2025 full-year result was $724000.0, up 122.09% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $736000.0, up from $724000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $750000.0 in Q4 2023, with the low at $326000.0 in Q4 2024.
- Average Other Accumulated Expenses over 5 years is $493916.7, with a median of $429000.0 recorded in 2025.
- Year-over-year, Other Accumulated Expenses slumped 56.53% in 2024 and surged 122.09% in 2025.
- Tracing NMRA's Other Accumulated Expenses over 5 years: stood at $408000.0 in 2022, then jumped by 83.82% to $750000.0 in 2023, then tumbled by 56.53% to $326000.0 in 2024, then surged by 122.09% to $724000.0 in 2025, then increased by 1.66% to $736000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $736000.0 (Q1 2026), $724000.0 (Q4 2025), and $449000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 736,000.00 |
| Dec 31, 2025 | 724,000.00 |
| Sep 30, 2025 | 449,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Mar 31, 2025 | 409,000.00 |
| Dec 31, 2024 | 326,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 366,000.00 |
| Mar 31, 2024 | 542,000.00 |
| Dec 31, 2023 | 750,000.00 |
| Sep 30, 2023 | 375,000.00 |
| Dec 31, 2022 | 408,000.00 |